Quince Therapeutics

News

Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.